Maprotiline (Ludiomil) in depression: a report of a monitored release study in general practice.
In a three-week study of 10,000 general practice patients with depressive illness, a once nightly dose of maprotiline 75 mg (Ludiomil) was effective therapy in three-quarters of the patients who completed the study. At this dose the drug was well tolerated, and troublesome side-effects presented in only a small percentage of patients. Drowsiness was the most commonly reported side-effect, and the main reason for stopping treatment. The drug was acceptable to most physicians, and in this study was used in a wide age range of patients and over a broad spectrum of depressive illness.
D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D000873:Anthracenes; D008376:Maprotiline